Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 92
- Registration Number
- NCT01072240
An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1653
- Registration Number
- NCT01071798
An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7
- Registration Number
- NCT01070927
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peginterferon alfa-2a (Pegasys®)
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4680
- Registration Number
- NCT01070550
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01069627
A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia
Phase 4
Terminated
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT01066000
- Locations
- 🇮🇩
Advent Hospital; Kidney and Hipertension, Bandung, Indonesia
🇮🇩Sanglah Hospital; Kidney and Hipertension, Denpasar, Indonesia
🇮🇩Rumah Sakit Pgi Cikini; Renal & Hypertension, Jakarta, Indonesia
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
Phase 4
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT01066884
PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peginterferon alfa-2a [Pegasys]Drug: Peginterferon alfa-2b [PegIntron®]
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1656
- Registration Number
- NCT01066819
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peginterferon alfa-2a [Pegasys]Drug: Peginterferon alfa-2b [PegIntron®]
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2343
- Registration Number
- NCT01066793
PRM-151 in the Prevention of Scarring Following Trabeculectomy
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 124
- Registration Number
- NCT01064817
- Locations
- 🇳🇱
UMC St. Radboud West, Nijmegen, Netherlands
🇬🇧Oxford Eye Hosiptal, Oxford, United Kingdom
🇬🇧St. Thomas, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath